PMID- 34439111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 16
DP  - 2021 Aug 5
TI  - Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients 
      with Unresectable Hepatocellular Carcinoma in Real-World Practice.
LID - 10.3390/cancers13163958 [doi]
LID - 3958
AB  - The aim of this study was to investigate the early tumor response and safety of 
      atezolizumab plus bevacizumab for patients with unresectable hepatocellular 
      carcinoma in real-world practice. Forty patients with Child-Pugh class A liver 
      function and eastern cooperative oncology group performance status 0 or 1 were 
      enrolled. The objective response rate (ORR) at six weeks after the start of 
      treatment, changes in alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin, incidence 
      of adverse events (AEs), and changes in albumin-bilirubin (ALBI) score and serum 
      ammonia level, were evaluated. Among 40 patients, 24 had histories of prior 
      molecular targeted agents (MTAs). The ORR was 22.5% based on mRECIST. 
      Multivariate analysis showed that an AFP ratio <1.0 at three weeks (odds ratio 
      39.2, 95% confidence interval CI 2.37-649.0, p = 0.0103) was the only significant 
      factor for predicting early response. There was no significant difference in the 
      frequency of AEs between patients receiving first-line treatments and others. 
      Fatigue, proteinuria, and ascites were more frequent in patients who experienced 
      prior treatment. No decrease in ALBI score or increase in serum ammonia level was 
      observed. Our study demonstrated that AFP may be useful in assessing early 
      response and that this treatment is safe, including in patients with prior MTA 
      treatments.
FAU - Ando, Yuwa
AU  - Ando Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kawaoka, Tomokazu
AU  - Kawaoka T
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kosaka, Masanari
AU  - Kosaka M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Shirane, Yuki
AU  - Shirane Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Johira, Yusuke
AU  - Johira Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Miura, Ryoichi
AU  - Miura R
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Murakami, Serami
AU  - Murakami S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Yano, Shigeki
AU  - Yano S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Amioka, Kei
AU  - Amioka K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Naruto, Kensuke
AU  - Naruto K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kosaka, Yumi
AU  - Kosaka Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Uchikawa, Shinsuke
AU  - Uchikawa S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kodama, Kenichiro
AU  - Kodama K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Fujino, Hatsue
AU  - Fujino H
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Nakahara, Takashi
AU  - Nakahara T
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Ono, Atsushi
AU  - Ono A
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Murakami, Eisuke
AU  - Murakami E
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Yamauchi, Masami
AU  - Yamauchi M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
AD  - Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima 
      734-8551, Japan.
FAU - Okamoto, Wataru
AU  - Okamoto W
AUID- ORCID: 0000-0002-2602-7282
AD  - Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima 
      734-8551, Japan.
FAU - Takahashi, Shoichi
AU  - Takahashi S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Imamura, Michio
AU  - Imamura M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Chayama, Kazuaki
AU  - Chayama K
AD  - Collaborative Research Laboratory of Medical Innovation, Hiroshima University, 
      Hiroshima 734-8551, Japan.
AD  - Research Center for Hepatology and Gastroenterology, Hiroshima University, 
      Hiroshima 734-8551, Japan.
AD  - RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
FAU - Aikata, Hiroshi
AU  - Aikata H
AUID- ORCID: 0000-0002-3409-2156
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210805
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8394131
OTO - NOTNLM
OT  - atezolizumab
OT  - bevacizumab
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitor
OT  - molecular targeted agents
OT  - real-world practice
OT  - tumor marker
OT  - alpha-fetoprotein
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/08/28 06:01
PMCR- 2021/08/05
CRDT- 2021/08/27 01:02
PHST- 2021/07/02 00:00 [received]
PHST- 2021/08/03 00:00 [revised]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/08/27 01:02 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/08/28 06:01 [medline]
PHST- 2021/08/05 00:00 [pmc-release]
AID - cancers13163958 [pii]
AID - cancers-13-03958 [pii]
AID - 10.3390/cancers13163958 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Aug 5;13(16):3958. doi: 10.3390/cancers13163958.